kidneys and semaglutide Semaglutide, Chronic Kidney Disease, Diabetes Ozempic Protects Kidneys, Boosts Survival

Boost GLP-1 levels by over 50% to promote satiety and feelings of fullness

While GLP-1 agonists do lead to a reduction in fat, they can also cause a loss of muscle if it isnt countered.

At study entry, 38% of the patients were taking sodium glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications for diabetes that have been shown to have beneficial effects on heart disease, including reducing heart failure, heart attacks and strokes

Purpose of Review This review explores the rationale and available evidence behind incretin-based therapies for metabolic dysfunction-associated steatotic disease (MASLD) and metabolic-associated steatohepatitis (MASH), focusing on glucagon-like peptide 1 (GLP-1) and glucagon (GCG) receptor dual agonists (GLP-1/GCG RAs)